Precision BioSciences, Inc. (DTIL), Tuesday announced that the U.S. Food and Drug Administration has granted Fast Track designation for PBGENE-HBV, a first-in-class gene editing therapy designed to eliminate the root cause of chronic hepatitis B.
Currently, the company is evaluating PBGENE-HBV in the ongoing global Phase 1 ELIMINATE-B trial, with clinical investigation in the United States, Moldova, Hong Kong, New Zealand, and the United Kingdom.
The clinical stage gene editing company anticipates to share updates on the full low-dose cohort, including multiple dose administrations, and data from higher dose levels throughout 2025.
In the pre-market hours, Precision's stock is trading at $4.77, up 6.95 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.